Article
Immunology
Jinye Zhu, Qian Wang, Yongjia Liu, Yujun Dong, Zeyin Liang, Yue Yin, Wei Liu, Weilin Xu, Yuhua Sun, Bingjie Wang, Qingyun Wang, Qingya Wang, Na Han, Hanyun Ren, Yuan Li
Summary: Donor-specific anti-HLA antibody (DSA) is a significant obstacle in haplo-HSCT, but our study found that DSA desensitization with intravenous immunoglobulin (IVIg) was effective in achieving similar engraftment rates and patient outcomes compared to DSA-negative patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Fumiya Wada, Junya Kanda, Satoshi Yoshioka, Takayuki Ishikawa, Takashi Akasaka, Yasunori Ueda, Hirokazu Hirata, Yasuyuki Arai, Kazuhiro Yago, Naoyuki Anzai, Mitsumasa Watanabe, Takashi Ikeda, Akihito Yonezawa, Kazunori Imada, Mitsuru Itoh, Toshiyuki Kitano, Tomoharu Takeoka, Masakatsu Hishizawa, Masaharu Nohgawa, Nobuyoshi Arima, Kousuke Asagoe, Tadakazu Kondo, Akifumi Takaori-Kondo
Summary: Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) are alternative options for treating patients without a HLA-matched donor. This study compared the outcomes of UCB and PTCy-haplo transplantation in hematological malignancy patients and found that overall survival was comparable between the two groups. Neutrophil and platelet engraftment were delayed in the UCB group, but nonrelapse mortality risk and graft-versus-host disease incidence were similar between the groups. UCB transplantation showed a lower relapse rate in acute myeloid leukemia patients.
Review
Immunology
Scott M. Krummey, Alison J. Gareau
Summary: Advances in hematopoietic stem cell transplant have led to changes in donor selection approach, including the use of haploidentical donors or permissive HLA mismatches. However, this may increase the risk of donor-specific HLA antibodies, which can limit engraftment. Desensitization treatments can effectively reduce HLA antibodies and improve transplant outcomes. The consideration and management of HLA antibodies in donor selection are increasingly important in HSCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Guangyang Weng, Zhiping Fan, Huiwen Xue, Fen Huang, Na Xu, Hua Jin, Sijian Yu, Zhixin Ye, Jingchao Fan, Li Xuan, Qifa Liu
Summary: The study found that haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome (BOS) compared to HLA-matched sibling donor stem cell transplantation. Additionally, the use of antithymocyte globulin (ATG) and mixed grafts may be protective factors in reducing the incidence of BOS.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yaya Chu, Julie-An Talano, Lee Ann Baxter-Lowe, James W. Verbsky, Erin Morris, Harshini Mahanti, Janet Ayello, Carolyn Keever-Taylor, Bryon Johnson, Rona S. Weinberg, Qiuhu Shi, Theodore B. Moore, Sandra Fabricatore, Brenda Grossman, Carmella van de Ven, Shalini Shenoy, Mitchell S. Cairo
Summary: Haploidentical transplantation with CD34-enriched cells and peripheral blood mononuclear cell addback results in rapid engraftment, sustained donor chimerism, and broad-based immune reconstitution.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Xin Li, Haibo Zhu, Tao Sui, Xingli Zhao, Qi Deng
Summary: This study explores the method of eliminating DSA in haplo-SCT. The combination therapy with daratumumab significantly reduces DSA levels and allows for successful haplo-SCT.
CELL TRANSPLANTATION
(2022)
Article
Hematology
Yibo Wu, Xiaoyu Lai, Jimin Shi, Yamin Tan, Yanmin Zhao, Jian Yu, Lizhen Liu, Wei Zhang, He Huang, Yi Luo
Summary: In haploidentical stem cell transplantation, donor selection is crucial for transplant outcomes. The study found that increasing donor age and female donors to male recipients were associated with poorer outcomes. Choosing a younger donor and avoiding female donors to male recipients could improve the success of haplo-SCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Immunology
Elisabet Van Loon, Baptiste Lamarthee, Thomas Barba, Sandra Claes, Maarten Coemans, Henriette de Loor, Marie-Paule Emonds, Priyanka Koshy, Dirk Kuypers, Paul Proost, Aleksandar Senev, Ben Sprangers, Claire Tinel, Olivier Thaunat, Amaryllis H. Van Craenenbroeck, Dominique Schols, Maarten Naesens
Summary: Through multiplex assay, we found that kidney transplant patients with donor-specific anti-human leukocyte antigen antibodies and histological rejection have increased levels of pro-inflammatory cytokines in blood. Even in patients without histological rejection, elevated pro-inflammatory cytokine levels can be observed. These findings challenge the concept of histology as the gold standard for identifying ongoing allo-immune activation after transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Amanda Lipsitt, Paula Arnold, Liying Chi, Katharine Carruthers, Sophia Folk, Sallyanne Fossey, Dinesh Keerthi, Ewelina Mamcarz, Ashok Srinivasan, Akshay Sharma
Summary: Pediatric and AYA patients who receive multiple blood transfusions are at high risk for developing DSAs. Desensitization strategies have been successful in reducing DSA burden, including the novel use of daratumumab.
PEDIATRIC BLOOD & CANCER
(2022)
Article
Hematology
Mahasweta Gooptu, Rizwan Romee, Andrew St Martin, Mukta Arora, Monzr Al Malki, Joseph H. Antin, Christopher N. Bredeson, Claudio G. Brunstein, Saurabh Chhabra, Ephraim J. Fuchs, Nilanjan Ghosh, Michael R. Grunwald, Christopher G. Kanakry, Natasha Kekre, Jospeh P. McGuirk, Ian K. McNiece, Rohtesh S. Mehta, Marco Mielcarek, Fillipo Milano, Dipenkumar Modi, Ran Reshef, Scott R. Solomon, Mark A. Schroeder, Edmund K. Waller, Yoshiro Inamoto, Robert J. Soiffer, Mary Eapen
Summary: After comparing outcomes of 2036 haploidentical and 284 matched unrelated donor (MUD) transplantations with posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, it was found that MUD transplants had lower acute GVHD and nonrelapse mortality rates, as well as higher disease-free and overall survival, especially in recipients of reduced-intensity regimens. However, no significant differences were observed in patients receiving myeloablative conditioning regimens, highlighting the importance of donor-recipient HLA matching for allogeneic transplantation.
Review
Immunology
Solaf Al-Awadhi, Marc Raynaud, Kevin Louis, Antoine Bouquegneau, Jean-Luc Taupin, Olivier Aubert, Alexandre Loupy, Carmen Lefaucheur
Summary: In this systematic review, meta-analysis, and critical appraisal, the impact of complement-activating anti-HLA DSAs on solid organ transplant outcomes was investigated. The study found that complement-activating anti-HLA DSAs were associated with an increased risk of allograft loss and rejection. These findings demonstrate the significant deleterious impact and independent prognostic value of circulating complement-activating anti-HLA DSAs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Sarah Haebe, Alessia Fraccaroli, Elena Stauffer, Dusan Prevalsek, Anna K. Zoellner, Heidrun Drolle, Hans-Joachim Stemmler, Martin Dreyling, Michael von Bergwelt-Baildon, Johanna Tischer
Summary: Haplo-HSCT has emerged as a valuable alternative for patients without an available HLA-matched donor, with similar outcomes to MRD and URD transplantations. Haplo-HSCT also has a lower incidence of GvHD and better survival rates.
Article
Cell Biology
Jing Liu, Xiang-Yu Zhao, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Xiao-Dong Mo, Yuan-Yuan Zhang, Xiao-Su Zhao, Yi-Fei Cheng, Kai-Yan Liu, Xiao-Jun Huang, Ying-Jun Chang
Summary: This study investigates the impact of donor-specific anti-HLA antibodies (DSA) levels on primary poor graft function (PGF) and graft rejection (GR) after haploidentical stem cell transplantation. The study found that high levels of DSA were associated with a higher incidence of PGF. DSA levels have an impact on the efficiency of rituximab desensitization, and a DSA MFI threshold is provided for predicting primary PGF and GR.
Article
Immunology
Rebeca Bailen, Jose Luis Vicario, Laura Solan, Irene Sanchez-Vadillo, Pilar Herrera, Maria Calbacho, Raquel Alenda, Jose Luis Lopez-Lorenzo, Karem Humala, Anabelle Chinea, Jose Sanchez-Pina, Antonio Balas, Miguel Angel Moreno, Javier Arzuaga, Virginia Pradillo, Nieves Dorado, Gillen Oarbeascoa, Javier Anguita, Jose Luis Diez-Martin, Mi Kwon
Summary: This study reports the experience of using desensitization treatments for patients with DSAs undergoing haplo-HSCT. The results show that utilizing desensitization strategies guided by DSAs intensity kinetics can effectively decrease DSA intensity and improve engraftment rates.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Asuka Tanaka, Kentaro Ide, Yuka Tanaka, Masahiro Ohira, Hiroyuki Tahara, Hideki Ohdan
Summary: Pretransplant desensitization with rituximab was found to enhance anti-donor CD4(+) T cell responses in DSA-positive transplant recipients, while IL-10(+) CD5(+) B cells were shown to suppress excessive responses of anti-donor CD4(+) T cells.
SCIENTIFIC REPORTS
(2021)
